|
Variables
|
Total (n = 640)
|
Control (n = 308)
|
Intervention (n = 332)
|
P-value**
|
|---|
|
n (%)
|
n (%)
|
n (%)
|
|---|
|
Age
|
Median (IQR)
|
31.9 (28.2–35.1)
|
31.7 (28.2–34.5)
|
32.1 (28.4–35.6)
| |
|
<35 years old
|
474 (74.1)
|
235 (76.3)
|
239 (72.0)
|
0.21
|
|
≥35 years old
|
166 (25.9)
|
73 (23.7)
|
93 (28.0)
|
|
Sex
|
Male
|
452 (70.6)
|
216 (70.1)
|
236 (71.1)
|
0.79
|
|
Female
|
188 (29.4)
|
92 (29.9)
|
96 (28.9)
|
|
Marital status
|
Single
|
195 (30.5)
|
89 (28.9)
|
106 (32.0)
|
0.44
|
|
Married/divorced
|
445 (69.5)
|
219 (71.7)
|
226 (68.1)
|
|
ART-naïve status
|
Naïve
|
606 (94.7)
|
289 (45.2)
|
317 (49.5)
|
0.35
|
|
Non-naïve
|
35 (6.0)
|
19 (6.2)
|
16 (4.8)
|
|
History of OIs*
|
Yes
|
182 (28.4)
|
91 (29.5)
|
91 (27.4)
|
0.55
|
|
No
|
458 (71.6)
|
217 (70.5)
|
241 (72.6)
|
|
Occupation
|
Employed
|
493 (77.0)
|
243 (78.9)
|
250 (75.3)
|
0.31
|
|
Unemployed
|
147 (23.0)
|
65 (21.1)
|
82 (24.7)
|
|
Time to be known infected ≥6 months
|
<6 months HIV-
|
156 (24.4)
|
69 (22.4)
|
87 (26.2)
|
0.31
|
| |
449 (70.0)
|
220 (71.0)
|
229 (69.0)
|
|
HIV transmission route (self-reported)
|
IV Drug use
|
297 (46.4)
|
136 (44.2)
|
161 (48.5)
|
0.27
|
|
Sexual and others
|
343 (53.6)
|
172 (55.8)
|
171 (51.5)
|
|
History of IDU
|
Yes
|
337 (52.7)
|
151 (49.0)
|
186 (56.0)
|
0.08
|
|
No
|
303 (47.3)
|
157 (51.0)
|
146 (44.0)
|
|
Viral hepatitis
|
Yes
|
207 (33.7)
|
92 (31.1)
|
115 (36.2)
|
0.18
|
|
No
|
407 (36.3)
|
204 (68.9)
|
203 (63.8)
|
|
History of TB
|
Yes treatment
|
99 (15.5)
|
53 (17.2)
|
46 (13.9)
|
0.24
|
|
No
|
541 (84.5)
|
255 (82.8)
|
286 (86.1)
|
|
Having an HIV infected family member
|
Yes
|
256 (40.0)
|
132 (42.9)
|
124 (37.3)
|
0.09
|
|
No
|
384 (60)
|
176 (57.1)
|
208 (62.7)
|
|
WHO clinical stage
|
Clinical stage 1 or 2
|
298 (46.6)
|
142 (46.1)
|
156 (47.0)
|
0.82
|
|
Clinical stage 3 or 4
|
342 (53.4)
|
166 (53.9)
|
176 (53.0)
|
|
BMI”
|
18+ kg/m2
|
409 (64.0)
|
188 (61.0)
|
221 (66.7)
|
0.15
|
|
<18 kg/m2
|
231 (36.0)
|
120 (39.0)
|
111 (33.3)
|
|
Hemoglobin level
|
<100 g/L
|
73 (11.4)
|
33 (10.7)
|
40 (12.0)
|
0.61
|
|
≥100 g/L
|
520 (81.2)
|
253 (82.1)
|
267 (80.4)
|
|
CD4 counts
|
Median (IQR)
|
83 (29–176)
|
82 (27–183)
|
84 (30–168)
|
0.90
|
|
<100 cells/μl
|
359 (56.1)
|
172 (55.8)
|
187 (56.3)
|
|
>100 cells/μl
|
281 (43.9)
|
136 (44.2)
|
145 (43.7)
|
|
VL at baseline (copies/ml)
|
<100.000
|
426 (66.7)
|
209 (67.9)
|
217 (65.6)
|
0.54
|
|
≥100,000
|
213 (33.3)
|
99 (32.1)
|
114 (34.4)
|
|
regimen
|
D4T/3TC/NVP ART^
|
533 (83.3)
|
258 (83.8)
|
275 (82.8)
|
0.75
|
|
Other regimens
|
107 (16.7)
|
50 (16.2)
|
57 (17.2)
|
|
Clinics
|
Halong CDC
|
307 (48.0)
|
168 (54.5)
|
139 (41.9)
|
0.001
|
|
Other clinics
|
333 (52.0)
|
140 (45.5)
|
193 (58.1)
|
- *OIs opportunistic infections, IDU Injecting drug use, TB tuberculosis, BMI Body Mass Index, ART Antiretroviral therapy, VL viral load
- **Chi-square test
